

Case Number:	CM14-0009439		
Date Assigned:	02/14/2014	Date of Injury:	07/09/2010
Decision Date:	06/24/2014	UR Denial Date:	01/14/2014
Priority:	Standard	Application Received:	01/24/2014

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Neurological Surgery and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

The injured worker is a 63-year-old female who was injured on July 9, 2010. The injured worker was diagnosed as having plantar fasciitis and internal derangement of the knee status post meniscectomy. The utilization review in question was rendered on January 14, 2014. The reviewer modified the request for 90 tablets of Celebrex 100mg to 60 tablets of Celebrex 100mg. The reviewer indicates the maximum dose for this medication for the management of osteoarthritis is 200 mg daily, although in the setting of rheumatoid arthritis or ankylosing spondylitis up to 400 mg daily can be provided.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

1 PRESCRIPTION OF CELEBREX 100MG, #90: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines NSAIDS, GI SYMPTOMS & CARDIOVASULAR RISK,.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines NSAIDS; SPECIFIC DRUG LIST AND ADVERSE EFFECTS Page(s): 70.

Decision rationale: According to the MTUS guidelines, the recommended dose for Celebrex is of 200 mg a day (single dose or 100mg twice a day). Celebrex can increase the risk of serious cardiovascular events and gastrointestinal effects, thus it should be given within the

recommended dose and liver and kidney function should be monitored regularly. Since the request does not specify the dosage to be administered daily. The request is not in accordance with the MTUS guidelines. As such, the request is considered not medically necessary.